Aviso: Este sitio agrega datos públicos oficiales de la FDA, ClinicalTrials.gov, PubMed y SEC EDGAR solo como referencia general. No constituye asesoramiento médico, diagnóstico, recomendaciones de tratamiento ni asesoramiento de inversión.

PubMed

Regulatory Challenges and Opportunities: A Review of U.S. Food and Drug Administration-Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular Devices.

PMID: 41276747 ·

M, a, h, i, m, a, , S, a, i, n, i, ;, , G, r, i, s, h, m, a, , K, c, ;, , A, d, r, i, a, n, , J, , W, i, l, l, i, a, m, s, ;, , P, a, u, l, , M, , C, o, p, l, a, n, ;, , L, a, u, r, a, , E, , G, r, e, s, s, l, e, r

RevistaTherapeutic innovation & regulatory science
Año
PMID41276747

Resumen

The integration of artificial intelligence (AI) and machine learning (ML) into medical devices has revolutionized healthcare, enhancing diagnostic accuracy and clinical decision-making. However, their rapid evolution poses challenges to traditional regulatory frameworks, particularly in ensuring safety and effectiveness. This review examines current Food and Drug Administration (FDA) regulatory pathways for AI/ML-enabled cardiovascular medical devices. It assesses the pre- and postmarket criteri

Fuente oficial

Ver en PubMed →

Datos obtenidos de PubMed / NCBI. Para consultar el texto completo y la información más reciente, remítase siempre al registro oficial.

↑